Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life

被引：0
|
作者：
Knudsen, L. Bjerre [1 ]
Nielsen, P. F. [1 ]
Steensgaard, D. B. [1 ]
Bloch, P. [1 ]
Lau, J. [1 ]
Agersoe, H. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
775
引用
收藏
页码：S305 / S306
页数：2
相关论文
共 50 条
  • [31] Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with glimepiride: all as monotherapy in type 2 diabetes
    Garber, A.
    Henry, R.
    Ratner, R.
    Garcia-Hernandez, P.
    Pattzi, H. M. Rodriguez
    Olvera-Alvarez, I.
    Hale, P. M.
    Zdravkovic, M.
    Bode, B.
    DIABETOLOGIA, 2008, 51 : S358 - S359
  • [32] Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial
    Finer, N.
    Al Hakim, M.
    Astrup, A.
    Harper, A.
    Lean, M.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Van Gaal, L.
    DIABETOLOGIA, 2009, 52 : S11 - S12
  • [33] The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
    Flint, A.
    Kapitza, C.
    Zdravkovic, M.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 958 - 962
  • [34] In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss
    Fonseca, V. A.
    Henry, R. R.
    Tabanera y Palacios, R.
    Brett, J.
    Plutzky, J.
    DIABETOLOGIA, 2010, 53
  • [35] Liraglutide, a Once-Daily Human GLP-1 Analog, Lowers Systolic Blood Pressure (SBP) Independently of Concomitant Antihypertensive Treatment
    Fonseca, Vivian
    Plutzky, Jorge
    Montanya, Eduard
    Colagiuri, Stephen
    Hansen, Charlotte
    Falahati, Ali
    Devries, J. Hans
    DIABETES, 2010, 59 : A79 - A79
  • [36] Liraglutide, a Once-Daily Human GLP-1 Analog, Is Equally Effective and Tolerated Independent of Administration Time (Morning vs Evening)
    Kaku, Kohei
    Rasmussen, Mads
    Katayama, Yasuyuki
    Seino, Yutaka
    DIABETES, 2009, 58 : A144 - A144
  • [37] Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2013, 37 : 322 - 322
  • [38] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
    Colagiuri, Steven
    Frid, Anders
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Vaag, Allan
    DIABETES, 2008, 57 : A164 - A165
  • [39] The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials
    Plutzky, J.
    Garber, A. J.
    Falahati, A.
    Toft, A. D.
    Poulter, N. R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 917 - 917
  • [40] Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
    Plutzky, J.
    Garber, A.
    Toft, A. D.
    Poulter, N. R.
    DIABETOLOGIA, 2009, 52 : S299 - S300
12345